5,010 Da (data not shown). MPEG (with a molecular weight of 2,000 Da) (Sigma-Aldrich Co.) was dried in a one-necked flask under vacuum and stirred at 105°C for 90 minutes before use.
FA-MPEG(2000)-PLA(3000) was synthesized in two steps. First, COOH-PEG(2000)-PLA(3000) diblock copolymer with a designed molecular weight of 3,000 Da was synthesized by opening the L-lactide ring, initiated by COOH-PEG.
COOH-PEG (5.0 g) was melted in a 50-mL flask following the addition of anhydrous L-lactide (7.5 g) and Sn(Oct)2 (1 mL) under nitrogen. The reactant mixture was maintained at 125°C for 24 hours. The crude product was dissolved in tetrahydrofuran and then purified by precipitation in ice-cold diethyl ether followed by filtration. This process was performed in triplicate, and the resulting product was vacuum dried at ambient temperature. The number average molecular weight (Mn) of FA-MPEG-PLA copolymer was 5,010 Da (data not shown). COOH-MPEG (with a molecular weight of 2,000 Da) (Sigma-Aldrich Co.) was dried in a one-necked flask under vacuum and stirred at 105°C for 90 minutes before use.
Second, folic acid was linked with ethylenediamine, and then coupled with PLA-PEG-COOH under DCC/NHS conditions to obtain the crude product. The final targeting polymer was further purified by dialysis to give TM as a white powder. The FA-PEG-PLA was characterized by 1 H NMR.
Molecular Dynamics
DOTAP was built at first with Marvin Sketch (http://www.chemaxon.com) and optimized at the molecular mechanical level with the MMFF94 method [1] . Then it was further optimized at the semiempirical level using the AM1 method [1] with the Fletcher-Reeves algorithm by employing Hyperchem software (HyperChem, Professional 8.0, Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA.). The structures of FA-PEG-PLA and DOTAP were constructed, optimized and simulated according to a strategy described in a published document [1] .
To understand in detail the mechanism by which DOTAP passively targets tumor tissue, interactions between the bi-block copolymer FA-PEG-PLA and DOTAP in different circumstances were investigated with molecular dynamics simulation.
DOTAP was docked randomly to the simulated bi-block copolymer FA-PEG-PLA at first by merging it to the FA-PEG-PLA in the workspace of HyperChem to obtain the initial structure of complex composed of DOTAP and FA-PEG-PLA. Then two stages of Langevin dynamics simulations were performed in an effort to explore interactions between the two components of the complex in water. In the process of simulation, the temperature, friction coefficient and random seed were set to 300K, 0.05 ps-1 and 0, respectively. CHARMM27, was chosen as the force field. At the first stage of simulation, interactions in water were simulated and the solvation effect was considered implicitly by setting the scale factor for the dielectric permittivity to 80. At the subsequent simulation stage, interactions near the tumor tissue were simulated by setting the scale factor. At each stage, the run time was set to 500 ps.
Preparation of F-DMA/CCL19
Fifteen milligrams of DOTAP, 15mg Fa-PEG-PLA and 70mg MPEG-PLA were dissolved in acetone (2 mL). The mixture was then placed into a round-bottom flask, and acetone was removed using a water bath (55℃) under negative pressure conditions (20min). Then, a 5% glucose solution (GS) (5 mL) was added to prepare the F-DMA gene carrier. At last, the CCL19 plasmid was added into F-DMA solution and F-DMA/CCL19 was obtained.
Characterization of F-DMA/CCL19
The morphological characteristics of F-DMA/CCL19 were observed using transmission electron microscopy (TEM; FEI Tecnai G 2 F20, Hillsboro, OR, US). The samples were diluted with distilled water, placed on a copper grid and negatively stained with molybdophosphoric acid for 1 min. The grid was then allowed to dry at room temperature and examined using TEM. The mean particle size and zeta potential of F-DMA/CCL19 were determined by a Zetasizer NanoZS ZEN 3600 (Malvern Instruments, Ltd., Malvern, Worcestershire, U.K.).
Agarose gel electrophoresis of naked plasmid DNA and F-DMA/CCL19 complexes
After F-DMA/CCL19 was prepared, agarose gel electrophoresis was conducted in pH 7.4 TAE buffer containing the nucleic acid stain Gold View. Briefly, F-DMA was mixed with CCL19 at increasing ratios (0:1, 5:1, 10:1, 50:1) to form complexes.
A gel retardation assay was conducted on a 1% agarose gel (Invitrogen Corp., Carlsbad, CA, U.S.) in Tris-acetate running buffer containing Gold View at 120 V for 20 min. The electrophoresis gels were digitally photographed using a gel documentation system (Bio-Rad Laboratories, Hercules, CA, U.S.).
In vitro immune cell stimulation test
The murine colon cancer cell line CT26 was purchased from the American Type Culture Collection (ATCC, Manassas,VA, USA) and routinely cultured in RPMI 1640 medium (Gibco-BRL, Rockville, IN, USA), containing 10% FBS (Sigma Chemical
Co., St. Louis, MO), 100 U/ml penicillin and 100μg/ml streptomycin. The cells were maintained in a humidified atmosphere containing 5% CO2 at 37°C. were subsequently added to designated wells and allowed to incubate for 5 h.
The supernatants in each group were then collected to culture spleen derived T lymphocytes and DCs, and peritoneal derived macrophages. The activation of T lymphocytes, maturation of DCs, and the polarization of macrophage were measured by flow cytometry. The supernatants were also applied to culture peritoneal macrophages to test the IFN-γ and TNF-α expression levels by ELISA.
In another test, the supernatants were further applied to culture lymphocytes derived from the spleen, and the lymphocyte proliferation after 24 h of culture was tested by the CCK-8 method and labeled with EdU, CD4 and CD8 to identify the cell type. In addition, the subsequent lymphocytes culture supernatants at 24h in each group were collected for the measurement of its cytotoxicity to CT26 tumor cell with CCK-8, and IFN-γ and TNF-α expression by ELISA.
Imaging In vivo
In vivo colon cancer mouse models were established by intraperitoneal injection 
Murine colon cancer model establishment
All animal experiments were performed in accordance with guidelines and approved by the Animal Care Committee of Sichuan University (Chengdu, China).
Female BALB/c mice (6-8 weeks old) were purchased from Vital River (Beijing, China) and housed in a specific-pathogen-free (SPF) environment with a consistent room temperature and humidity and handled in strict accordance with good animal practice.
In vivo colon cancer mouse models were established by the subcutaneous (s.c.)
injection of CT26 cells (1*10 6 cells/0.2 mL serum-free RPMI-1640) or intra-peritoneal injection of 5*10 5 CT26 cells. Mice were randomly allocated into five groups (GS, F-DMA, F-DMA/pVax, DMA/CCL19, F-DMA/CCL19).
To assess the tumor growth of the subcutaneous model, treatment began six days Tumor immune microenvironment were determined using Immunofluorescence analysis using a rabbit anti-mouse CD8 and F4/80 antibody (Abcam) with a secondary antibody labeled with FITC detection method. according to the manufacturer's instructions.
Toxicity assessment
To evaluate the potential F-DMA/CCL19 treatment associated toxicity, the vital organs tissues (heart, liver, spleen, lung and kidney) of the treated mice were harvested, fixed in 4% paraformaldehyde solution, embedded in paraffn and sectioned at 5 μm. The sections were hydrated and stained with hematoxylin and eosin (H&E)
for histomorphometric analysis and observed by two pathologists in a blinded manner with a 4-point scoring system (Supplementary Table 1 ) [2] . In addition, blood and serum were harvested for routine blood tests and biochemical parameter tests. Blood cell counts were analyzed using an automated veterinary haematological analyzer with a preprogrammed murine calibration mode (Hemavet 950FS; Drew Scientific, Waterbury, CT). Hepatic and renal function was analyzed in a Hitachi Automatic Analyzer (Boehringer, Indianapolis, IN).
Statistical analysis
All data were analyzed using GRAPHPAD PRISM software (GraphPad, San Diego, CA). Data from multiple groups were analyzed using ANOVA. 
Safety statement
No unexpected or unusually high safety hazards were encountered. 1 Minimal The amount of change present barely exceeds that which is considered to be within normal limits.
Reference
2 Slight In general, the lesion is easily identified but of limited severity.
3 Moderate The lesion is prominent but there is significant potential for increased severity.
